Literature DB >> 1952872

In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.

N Rastogi1, K S Goh.   

Abstract

MICs of the new fluoroquinolone drugs ofloxacin, ciprofloxacin, and sparfloxacin (AT-4140) for 10 strains of Mycobacterium tuberculosis were determined by using both a BACTEC radiometric method and testing on solid 7H11 agar medium. Radiometric MICs by 7H12 broth testing ranged from 0.5 to 1.0, 0.25 to 0.5, and 0.1 to 0.2 microgram/ml for ofloxacin, ciprofloxacin, and sparfloxacin respectively, whereas MICs in solid medium ranged from 0.5 to 1.0, 0.5 to 1.0, and 0.2 to 0.5 microgram/ml, respectively. The bactericidal action of the quinolones compared with their reported peak concentrations in human serum showed that sparfloxacin is the most bactericidal, followed by ciprofloxacin and ofloxacin. Our results suggest the potential of the new difluorinated quinolone sparfloxacin for use against the tubercle bacillus and indicate that further determination of its antimycobacterial spectrum and intracellular efficacy may be fruitful.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1952872      PMCID: PMC245298          DOI: 10.1128/AAC.35.9.1933

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.

Authors:  O G Berlin; L S Young; D A Bruckner
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

4.  Pharmacokinetics of a novel quinolone, AT-4140, in animals.

Authors:  S Nakamura; N Kurobe; T Ohue; M Hashimoto; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 5.  Tissue penetration of the new quinolones in humans.

Authors:  D N Gerding; J A Hitt
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

6.  Intracellular bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis H37Rv multiplying in the J-774 macrophage cell line.

Authors:  N Rastogi; M C Blom-Potar
Journal:  Zentralbl Bakteriol       Date:  1990-06

7.  Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  S H Siddiqi; J P Libonati; G Middlebrook
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

8.  Comparative in-vitro activity of five fluoroquinolones against mycobacteria.

Authors:  S Davies; P D Sparham; R C Spencer
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

9.  In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin.

Authors:  D M Yajko; C A Sanders; P S Nassos; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

10.  Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis.

Authors:  N Rastogi; K S Goh; H L David
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

View more
  18 in total

1.  Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 2.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

Review 3.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

4.  Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages.

Authors:  N Rastogi; V Labrousse; K S Goh; J P De Sousa
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

5.  Antimycobacterial activities of novel levofloxacin analogues.

Authors:  K Kawakami; K Namba; M Tanaka; N Matsuhashi; K Sato; M Takemura
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 6.  Quinolones in intracellular infections.

Authors:  J C Pechère
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Activity of subinhibitory concentrations of dapsone alone and in combination with cell-wall inhibitors against Mycobacterium avium complex organisms.

Authors:  N Rastogi; K S Goh; V Labrousse
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

8.  Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice.

Authors:  R H Gelber; A Iranmanesh; L Murray; P Siu; M Tsang
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

9.  Intracellular accumulation of norfloxacin in Mycobacterium smegmatis.

Authors:  S Corti; J Chevalier; A Cremieux
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

Review 10.  Activity of quinolones against mycobacteria.

Authors:  M R Jacobs
Journal:  Drugs       Date:  1995       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.